BACKGROUND: CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. METHODS: Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). RESULTS: CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8,112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. CONCLUSION: CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.
BACKGROUND:CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. METHODS: Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). RESULTS:CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8,112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. CONCLUSION:CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.
Authors: E K Page; A J Page; J Kwun; A C Gibby; F Leopardi; J B Jenkins; E A Strobert; M Song; R A Hennigar; N Iwakoshi; S J Knechtle Journal: Am J Transplant Date: 2012-07-09 Impact factor: 8.086
Authors: M B Ezzelarab; D Raich-Regue; L Lu; A F Zahorchak; A Perez-Gutierrez; A Humar; M Wijkstrom; M Minervini; R W Wiseman; D K C Cooper; A E Morelli; A W Thomson Journal: Am J Transplant Date: 2017-02-02 Impact factor: 8.086
Authors: Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle Journal: Transplant Rev (Orlando) Date: 2019-04-05 Impact factor: 3.943
Authors: T Zhang; S Fresnay; E Welty; N Sangrampurkar; E Rybak; H Zhou; X-F Cheng; Q Feng; C Avon; A Laaris; M Whitters; A M Nagelin; R M O'Hara; A M Azimzadeh Journal: Am J Transplant Date: 2011-07-12 Impact factor: 8.086
Authors: Nicolas Poirier; Agnes M Azimzadeh; Tianshu Zhang; Nahzli Dilek; Caroline Mary; Bao Nguyen; Xavier Tillou; Guosheng Wu; Karine Reneaudin; Jeremy Hervouet; Bernard Martinet; Flora Coulon; Emma Allain-Launay; Georges Karam; Jean-Paul Soulillou; Richard N Pierson; Gilles Blancho; Bernard Vanhove Journal: Sci Transl Med Date: 2010-02-03 Impact factor: 17.956